Gene therapy for bladder cancer

Lance C. Pagliaro

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Tumor-suppressor genes can be transferred into tumor cells in vivo using a replication-defective adenoviral vector. P53 mutations are frequent in bladder cancer, and adenovirus-mediated p53 gene transfer is growth-inhibitory to bladder cancer cells in vitro. The vector Ad5CMV-P53, which contains human wild-type p53, is being administered intravesically to patients with bladder cancer in a phase I clinical trial. The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation.

Original languageEnglish (US)
Pages (from-to)148-151
Number of pages4
JournalWorld Journal of Urology
Volume18
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Genetic Therapy
Clinical Trials, Phase I
p53 Genes
Tumor Suppressor Genes
Adenoviridae
Urinary Bladder
Mutation
Growth
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Pagliaro, L. C. (2000). Gene therapy for bladder cancer. World Journal of Urology, 18(2), 148-151.

Gene therapy for bladder cancer. / Pagliaro, Lance C.

In: World Journal of Urology, Vol. 18, No. 2, 2000, p. 148-151.

Research output: Contribution to journalArticle

Pagliaro, LC 2000, 'Gene therapy for bladder cancer', World Journal of Urology, vol. 18, no. 2, pp. 148-151.
Pagliaro, Lance C. / Gene therapy for bladder cancer. In: World Journal of Urology. 2000 ; Vol. 18, No. 2. pp. 148-151.
@article{75df80cb39254d35b897317bb9efeb21,
title = "Gene therapy for bladder cancer",
abstract = "Tumor-suppressor genes can be transferred into tumor cells in vivo using a replication-defective adenoviral vector. P53 mutations are frequent in bladder cancer, and adenovirus-mediated p53 gene transfer is growth-inhibitory to bladder cancer cells in vitro. The vector Ad5CMV-P53, which contains human wild-type p53, is being administered intravesically to patients with bladder cancer in a phase I clinical trial. The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation.",
author = "Pagliaro, {Lance C.}",
year = "2000",
language = "English (US)",
volume = "18",
pages = "148--151",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Gene therapy for bladder cancer

AU - Pagliaro, Lance C.

PY - 2000

Y1 - 2000

N2 - Tumor-suppressor genes can be transferred into tumor cells in vivo using a replication-defective adenoviral vector. P53 mutations are frequent in bladder cancer, and adenovirus-mediated p53 gene transfer is growth-inhibitory to bladder cancer cells in vitro. The vector Ad5CMV-P53, which contains human wild-type p53, is being administered intravesically to patients with bladder cancer in a phase I clinical trial. The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation.

AB - Tumor-suppressor genes can be transferred into tumor cells in vivo using a replication-defective adenoviral vector. P53 mutations are frequent in bladder cancer, and adenovirus-mediated p53 gene transfer is growth-inhibitory to bladder cancer cells in vitro. The vector Ad5CMV-P53, which contains human wild-type p53, is being administered intravesically to patients with bladder cancer in a phase I clinical trial. The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation.

UR - http://www.scopus.com/inward/record.url?scp=0034170763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034170763&partnerID=8YFLogxK

M3 - Article

C2 - 10854151

AN - SCOPUS:0034170763

VL - 18

SP - 148

EP - 151

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 2

ER -